×
About 103 results

ALLMedicine™ Coronary Drug-eluting Stent Center

Research & Reviews  35 results

Ultrathin biodegradable polymer sirolimus-eluting stent versus contemporary durable pol...
https://doi.org/10.1097/MCA.0000000000000949
Coronary Artery Disease; Sethi A, Kodumuri V et. al.

Sep 8th, 2020 - Improvements in coronary drug-eluting stent technology has focused on reducing the long-term complications associated with the effects of the residual footprint on the vessel wall. Although many of the newer stents have exhibited noninferiority to...

Coronary Intravascular Brachytherapy for Recurrent Coronary Drug-Eluting Stent In-Stent...
https://doi.org/10.1016/j.carrev.2020.08.035
Cardiovascular Revascularization Medicine : Including Mol... Megaly M, Glogoza M et. al.

Sep 4th, 2020 - To examine the outcomes with intravascular brachytherapy (IVBT) in recurrent in-stent restenosis (ISR). Recurrent ISR can be challenging to treat and IVBT can be used for recurrent ISR but has received limited study. We performed a systematic revi...

Use of artificial intelligence as innovative method for liver graft macrosteatosis asse...
https://doi.org/10.1002/lt.25801
Liver Transplantation : Official Publication of the Ameri... Cesaretti M, Brustia R et. al.

May 18th, 2020 - We sought to compare in-hospital outcomes between patients with and without end-stage renal disease (ESRD) undergoing coronary drug-eluting stent (DES) placement and to model risk of in-hospital adverse postpercutaneous coronary intervention (PCI)...

End-stage renal disease as an independent risk factor for in-hospital mortality after c...
https://doi.org/10.1002/ccd.28929
Catheterization and Cardiovascular Interventions : Offici... Dunn AN, Huded C et. al.

May 18th, 2020 - We sought to compare in-hospital outcomes between patients with and without end-stage renal disease (ESRD) undergoing coronary drug-eluting stent (DES) placement and to model risk of in-hospital adverse postpercutaneous coronary intervention (PCI)...

Coronary Drug-Eluting Stent Infection Complicated by Coronary Artery Aneurysm and Purul...
https://doi.org/10.1016/j.cjca.2020.01.007
The Canadian Journal of Cardiology; Riku S, Suzuki S et. al.

May 14th, 2020 - Coronary stent infection is considered to be a rare but catastrophic complication of percutaneous coronary intervention. In this report, we present a 72-year-old man who developed a coronary stent infection complicated by coronary aneurysm and pur...

see more →

Clinicaltrials.gov  3 results

Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting Stent Trial
https://clinicaltrials.gov/ct2/show/NCT01035450

Dec 9th, 2015 - Sirolimus-eluting stent is the most widely used coronary drug-eluting stent in Japan. Everolimus-eluting stent is a new coronary drug-eluting stent, which is going to be approved in the first quarter of 2010 by the Japanese Ministry of Health, Lab...

NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-eluting Stent Trial
https://clinicaltrials.gov/ct2/show/NCT01303640

Dec 9th, 2015 - Everolimus-eluting stent is the most widely used coronary drug-eluting stent in Japan. Biolimus-eluting stent is a new coronary drug-eluting stent, which is going to be approved in 2011 by the Japanese Ministry of Health, Labor and Welfare. It has...

ProStent Coronary Drug-Eluting Stent
https://clinicaltrials.gov/ct2/show/NCT00887211

A single blind, multi-center, randomized study is preformed to compare ProStent drug-eluting stents with Firebird drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd. to evaluate the safety and efficacy of ProStent drug-eluting stent in...

see more →

News  3 results

BIOFLOW V: Orsiro outperforms Xience stent
https://www.mdedge.com/cardiology/article/178950/interventional-cardiology-surgery/bioflow-v-orsiro-outperforms-xience
Susan London

Nov 5th, 2018 - SAN DIEGO – Seemingly nuanced differences between drug-eluting stents can translate to substantial differences in clinical outcomes longer term, updated results of the BIOFLOW V randomized trial reported at the Transcatheter Cardiovascular Therape.

Reigning Coronary DES King Matches Its Predecessor
https://www.mdedge.com/internalmedicine/article/37228/cardiology/reigning-coronary-des-king-matches-its-predecessor
Mitchel L. Zoler

Aug 30th, 2011 - PARIS – The current master of the coronary drug-eluting stent universe, the everolimus-eluting stent, finally proved itself fully worthy of its position, matching the efficacy and safety performance of its predecessor, the sirolimus-eluting corona.

Coronary Drug-Eluting Stent Safety Diminishes Over Time
https://www.medpagetoday.com/cardiology/pci/12228

Dec 18th, 2008 - Action Points Explain to interested patients that this study suggests that both drug-eluting and bare-metal stents have good long-term safety profiles. Explain to patients who ask that a number of factors influence the choice of stent type. Explai...

see more →